Gartner Inc vs Sanofi SA — how do they compare? Gartner Inc trades at $141.17 (market cap $9.44B), while Sanofi SA trades at $44.05 (market cap $104.83B). The key difference: Sanofi SA is far larger — about 11.1× Gartner Inc's market cap, and Sanofi SA pays a 5.5% dividend while Gartner Inc pays none. Which is the better fit depends on your goals.
| IT | SNY | |
|---|---|---|
Market Cap | $9.44B | $104.83B |
Sector | Technology | Health |
52-Week High | $357.98 | $52.34 |
52-Week Low | $125.68 | $41.33 |
Enterprise Value | $11.04B | $121.32B |
Dividend Yield | — | 5.5% |
Signals from Pluang's Aura AI — not financial advice
Gartner (IT) trades at $141.06, up 0.62% today, with a neutral technical signal and mixed analyst sentiment. The stock shows strong profitability with a net income margin of 11.44% and has beaten earnings estimates for three consecutive quarters. Recent news highlights its leadership in Gartner Magic Quadrant reports, but an ongoing legal investigation adds uncertainty. Cash flow turned negative in 2025 due to high financing outflows, though revenue remains stable around $6.5 billion.
The outlook is cautiously optimistic with a consensus price target of $157.60 suggesting 12% upside. Key opportunities include steady revenue growth and high ROE of 94.88%, but risks involve the legal probe, elevated P/B ratio of 148.08, and volatile cash flows. Investors should weigh strong fundamentals against near-term headwinds.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →